[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)
[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)

President Donald Trump – Will He Become the Drug Price Equalizer?

By:Posted: May 13th, 2025In: Opinions & Features

Published in Forbes, May 13, 2025

Dr. Steve Brozak, President of WBB Securities, has authored a new opinion piece in Forbes exploring President Donald Trump’s evolving role in the fight to lower drug prices in America.

In the article, Dr. Brozak examines:

  • Trump’s past and current positions on drug pricing reform
  • The potential political and market impact of drug price equalization

“The reality is that drug pricing affects every American, and whoever speaks to that challenge in a credible way will command attention,” Brozak writes.

📖 Read the full article on Forbes:
👉 President Donald Trump – Will He Become the Drug Price Equalizer?

This article was written by Dr. Steve Brozak and originally published by Forbes on May 13, 2025.

Recent Posts